Seeking Alpha

Wedbush cuts Synageva BioPharma to Neutral in valuation call

  • Wedbush cuts Synageva BioPharma (GEVA) to Neutral from Outperform.
  • "We can no longer recommend purchase of GEVA shares at current levels," analyst David Nierengarten says, noting that the stock trades at an EV/2017 sales ratio of 9, well above peers.
  • Price target is $67.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs